Usha Yendrapalli
Pulmonary Disease · Mobile, ALNPI 1689038283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $481 and has fallen 51.9% since, to $231 in 2025. That places this record below the midpoint for pulmonary disease clinicians in AL, where the typical reported total is $3,082.
Across 79 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$241
- Johnson & Johnson$184
- Merck$162
- United Therapeutics Corporation$134
- AbbVie$125
- Pfizer$125
- plus $567 from 13 others
What the payments were for
- Food & beverage$1,44694%
- Education$906%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 8 | $241 |
| Johnson & Johnson | 13 | $184 |
| Merck | 8 | $162 |
| United Therapeutics Corporation | 5 | $134 |
| AbbVie | 7 | $125 |
| Pfizer | 8 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $106 |
| Boehringer Ingelheim | 4 | $90 |
| AstraZeneca(2 entities) | 5 | $84 |
| Sanofi | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Pulmonx Corporation | 1 | $32 |
| Convatec Inc. | 1 | $29 |
| Inari Medical, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Gilead | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,536 in reported general payments places this provider in the 40th percentile of 215 pulmonary disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,776 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,920 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $90 | $6,92013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Mobile
- Adrian DivittorioMobile$100K
- Peter LutzMobile$63K
- Virginia RadcliffMobile$23K
- Johnson HaynesMobile$21K
- Cynthia CrowderMobile$20K
- Philip AlmaloufMobile$14K
- Campbell SindelMobile$14K
- Chibuzo OdigweMobile$14K
- Caesar AgaganMobile$11K
- James DeanMobile$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.